Evaluation of new biomarkers in routine follow up after kidney transplantation

Conditions

T86.1

Reineke M, Loi L, Schröter I, Zeier M, Beck J, Schütz E, Schweitzer BL, Oellerich M, Akifova A, Budde K, Tran TH, Morath C, Benning L.

2026-06-11

10.1093/clinchem/hvag056

Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy—Results of a Prospective Single-Center Trial

Louise Benning, Christian Morath, Annette Fink, Markus Rudek, Claudius Speer et al. (13 authors)

Transplant International2023-11-0330 citations

10.3389/ti.2023.11899

Interventions

Group 1: t0= time of indicated biopsy, assessing Patient and transplant relevant data, collection of Serum, EDTA, Urine and biopsy material t1=7d after biopsy, collection of Serum, EDTA, Urine and bi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Renal transplanted Patient with indication to graft biopsy Gillick competent Agrees to participation

Exclusion criteria

Exclusion criteria: <18years of age, pregnant, not gillick competent

Design outcomes

Primary

Measure	Time frame
Concentrations of different biomarkers in their timely course at defined intervals (day of biopsy, 7d post biopsy, 30d post biopsy, 90d post biopsy), correlation to result of biopsy and graft failure	—

Secondary

Measure	Time frame
Evaluating a possible response to treatment (to i.e. cortison pulse therapie) with the help of the timely course of different biomarkers at day7 post biopsy, day30 post biopy, day 90 post biopsy	—

Countries

Germany

Outcome results

None listed